News

Lipoplatin RT: Clinical studies pioneered by Professor Koukourakis at the University Hospital of Alexandroupolis using fractions of radiation therapy (RT) in combination with Lipoplatin against gastric cancer patients have shown up to 80% complete response. Lipoplatin weekly 120 mg/m2 (D1). 5-FU weekly 400 mg/m2 (D1). Radiotherapy at 3.5-Gy fractions on Days 2,3,4.

RESULTS: 4 of 5 patients had complete response after 5 weekly cycles (Koukourakis et al, 2010 Int J Radiation Oncology Biol Phys 78, 150-155).

Phase I-II trial of Lipoplatin (dose escalation) and Gemcitabine as a second-line chemotherapy in patients with advanced pancreatic cancer (24 patients)

Stathopoulos et al, Oncol Rep 15, 1201-1204 (2006)

Partial response in 2/24 patients (8.3%), disease stability in 14 patients (58.3%) for a median duration of 3 months (range 2-7 months) and clinical benefit in 8 patients (33.3%).

Phase I trial of Lipoplatin (dose escalation) and Gemcitabine as a second-line chemotherapy in patients with non small cell lung carcinoma (13 patients)

Froudarakis et al, Cancer 113:2752-60 (2008)

The first dose escalation and pharmacokinetic study reported for the comb...

In 2012 Dr. Stathopoulos published a study on the application of Lipoplatin on patients with renal dysfunction. Usually patients with creatinine levels of 1.6 to 4.0 mg/dl or with a Glomerular Filtration Rate (GFR) of less than 60 ml/min cannot be treated with chemotherapy. In all oncology protocols one of the standard exclusion criteria is renal insufficiency (patients with creatinine levels above 1.6 mg/dl are excluded from all oncology protocols).

In the Stathopoulos  study 42 patients mainly with lung and bladder cancers with renal insufficiency (creatinine levels 1.6 to 4.0 mg/ dl) were treated with Lipoplatin monotherapy or with its combination with gemcitabine, paclitaxel, or 5-fluor...

Passive tumor targeting 

Passive delivery to tumors is achieved secretly from immune cells and normal tissues by encapsulation of cisplatin into a natural lipid capsule protected ...